小细胞肺癌分子靶向治疗研究进展

分子靶向治疗药物包括抗肿瘤血管生成剂、生长因子受体抑制剂、Scr酪氨酸激酶抑制剂、重组分子N-901、抗细胞凋亡因子Bcl-2抑制剂、Hh信号通路抑制剂等.其中抗肿瘤血管生成剂如贝伐单抗和沙力度胺均进行了大量的Ⅱ、Ⅲ试验研究用以评估其在治疗小细胞肺癌(SCLC)方面的疗效及毒性;Scr酪氨酸激酶抑制剂正在进行Ⅰ、Ⅱ期的临床试验,结果 尚未得出;重组分子N-901也正在进行一项针对广泛期SCLC的Ⅱ期的临床试验,另外Bcl-2及Hh信号通路抑制剂正在进行初期的临床试验.初步的研究数据表明SCLC对于靶向治疗不敏感,其原因有待于进一步研究.

Recent advances of molecular targeted therapy in small cell lung cancer

Molecular targeted agents for small cell lung cancer have been introduced in great many clinical trials in recent years. The classes of targeted agents include antiangiogenic agents,growth factor receptor inhibitors,Bcl-2 inhibitors,SCR kinase inb.ibitors, recombinant molecules N-901 and inhibitors of the sonic hedgehog signaling pathway. The class of antiangiogenic agents,including bevacizumab and thalidomide,is be-ing evaluated in phase Ⅱ and Ⅲ trials. The tyrosine and Scr kinase inhibitors are being evaluated in phase Ⅰ and Ⅱ trials. The recombinant molecule, N-901 is undergoing phase Ⅱ testing in patients with relapsed small cell lung cancer. The other pathways undergoing evaluation for the development of pharmacologic agents include inhibiturs of bcl-2 and sonic hedgehog signaling,which are being tested in the earliest phases of clinical evalua-tion. Primary data shows small cell lung cancer is not sensitive to targeted therapy and further studies are re-quested.